ASCO 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
Dr. Denmeade highlights his research on blood-based markers of differential efficacy of BAT and enzalutamide in TRANSFORMER.
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
KIM-1 levels were evaluated using a high-sensitivity electrochemiluminescence assay.
Trial data showed that patients who received the combination therapy experienced improved OS, PFS, and ORR.
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Intensified androgen blockade improves PSA progression-free survival in prostate cancer without affecting quality of life.
NECTIN4 mRNA expression as a biomarker for EV therapy linked to better outcomes in advanced urothelial carcinoma.
Investigators quantified baseline and week 9 serial ctDNA samples through FoundationOneLiquid CDx.
Of the 26 patients with pathological assessment upon safety visit, all reached pCR, while none received cystectomy.
The ArteraAI MMAI prognostic biomarker performs risk stratification of patients with localized prostate cancer.
Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
Dr. Moussa provides an overview of his research on prognostic factors of relapse in small cell neuroendocrine carcinomas.
Drs. Kyriakopoulos and Koshkin break down the CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group.
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Disitamab vedotin, a novel anti-HER2 antibody-drug conjugate, was paired with toripalimab, an anti–PD-1 monoclonal ...
New results of CheckMate 67T focused on additional safety analyses and patient-reported outcomes.
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
The real-world OS rates and risk of major adverse cardiovascular events of enzalutamide and abiraterone were compared.
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
![[177Lu]Lu-PSMA-617 Delays TTW in Patients With Taxane-Naïve mCRPC Over ARPIs](https://mumcdnstorage.blob.core.windows.net/guonc/2022/10/PSMA-Immunohistochemistry-800x400-1.png)
New results of the PSMAfore study’s second interim analysis include health-related quality of life and pain outcomes.
New data compared patient response to 68Ga with PSA response in mCRPC treated with enzalutamide as a first-line therapy.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
In this study, Dr. Shilpa Gupta and colleagues examined patient-reported outcomes from the landmark EV-302 trial.
EV-302 trial: Enfortumab vedotin and pembrolizumab improve outcomes vs standard chemotherapy in advanced urothelial cancer.
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Dr. van der Heijden presents a follow-up analysis of patients who were cisplatin-ineligible at randomization for EV-302.
CYCLONE 2 evaluated the efficacy and safety of adding abemaciclib to abiraterone for the treatment of mCRPC.
New prognostic model using ctDNA enhances survival prediction in metastatic prostate cancer, improving patient stratification
A retrospective analysis of ctDNA data by clinical outcomes with pembro vs chemotherapy for aUC from KEYNOTE-361.
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.